<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>Myeloid growth factors are used to reduce myelotoxicity and the risk of <z:e sem="disease" ids="C0021311,C0009450" disease_type="Disease or Syndrome" abbrv="">infection</z:e> after <z:e sem="disease" ids="C1306459,C0006826" disease_type="Neoplastic Process" abbrv="">cancer</z:e> chemotherapy and in patients with <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>This article addresses the long-term benefits and risks associated with granulocyte colony-stimulating factor (G-CSF) therapy in both settings </plain></SENT>
<SENT sid="2" pm="."><plain>A systematic review of randomized controlled trials recently reported long-term outcomes regarding the risk of <z:e sem="disease" ids="C0085183" disease_type="Neoplastic Process" abbrv="">second malignancies</z:e> and overall survival </plain></SENT>
<SENT sid="3" pm="."><plain>Based on these studies, the risk for <z:hpo ids='HP_0004808'>acute myeloid leukemia</z:hpo> (<z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>) associated with known <z:chebi fb="0" ids="50903">carcinogenic agents</z:chebi>, such as chemotherapy, could not be distinguished from any risk associated with growth factor support </plain></SENT>
<SENT sid="4" pm="."><plain>However, the enhanced delivery of chemotherapy dose intensity enabled by the use of G-CSF in these studies was associated with a significant reduction in <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="5" pm="."><plain>Although some reduction in treatment-related mortality with G-CSF support may occur, the observed improvement in long-term survival likely relates to better disease control with more-intense G-CSF-supported chemotherapy </plain></SENT>
<SENT sid="6" pm="."><plain>Myeloid growth factors have also been shown to benefit patients with severe <z:hpo ids='HP_0011010'>chronic</z:hpo> <z:hpo ids='HP_0001875'>neutropenia</z:hpo> </plain></SENT>
<SENT sid="7" pm="."><plain>Almost <z:hpo ids='HP_0000001'>all</z:hpo> patients with cyclic, congenital, or idiopathic <z:hpo ids='HP_0001875'>neutropenia</z:hpo> experience response to G-CSFs </plain></SENT>
<SENT sid="8" pm="."><plain>Treatment is titrated to determine a dose that provides a safe elevation in neutrophil counts </plain></SENT>
<SENT sid="9" pm="."><plain>Reports have shown that patients can be maintained for years at the same dose after adjusting for growth and development </plain></SENT>
<SENT sid="10" pm="."><plain>In <z:hpo ids='HP_0005549'>congenital neutropenia</z:hpo>, the inherent risk of developing <z:hpo ids='HP_0002863'>myelodysplastic syndromes</z:hpo> or <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> requires careful monitoring, including routine blood counts and annual bone marrow examinations </plain></SENT>
</text></document>